All News

We’re about to lose the most tech-savvy FDA chief in recent memory, writes Pratap Khedkar.

Brenda Snow talks to Pharm Exec about the creation of Snow Companies, the first full-service agency to bring strategic, regulatory-compliant, real-life patient stories to direct-to-patient initiatives.

Click the title above to open the Pharmaceutical Executive March 2019 issue in an interactive PDF format.

After a prolonged period of relative stagnation, the strategically influential, clinically rich French life sciences market suddenly seems to be rediscovering its mojo-thrusting the pharma and medtech sectors into the spotlight.

Purdue Pharma and its corporate leadership featured prominently in the media recently as litigation mounts over their sales and marketing of Oxycontin. Nir Kossovsky offers some observations about the lessons this situation provides for all corporate leaders responsible for their companies’ reputations.

This month's DIA Europe meeting saw the patient voice turned up to high volume, with advocates, regulators and industry representatives pushing the patient empowerment and engagement line.

Mark Taylor writes about the life and legacy of Milan Panic in new book titled, “Warrior CEO”.

New HHS proposal would remove the current safe harbor protection from the federal Anti-Kickback Statute for rebates or discounts provided to Medicare Part D drug plans and certain state Medicaid programs.

Click the title above to open the Pharmaceutical Executive February 2019 issue in an interactive PDF format.

With Spain now squarely on the road to economic recovery following the ravages of the global financial crisis, multinational pharmaceutical companies are seeing the country as a top-tier investment destination once more.

The Institute for Clinical Effectiveness Review (ICER) has set up a working group to bring together the expertise of NICE and other key HTAs to develop new methods to guide value-based pricing of potential cures. Leela Barham reports.

The introduction of biosimilars has been one of the biggest milestones in autoimmune treatment, but an air of uncertainty still lingers around the true impact of these new players. So what has happened in the market since their arrival?

DIA Europe proves to have excellent timing to learn more about the latest developments in drug development, the current status of Brexit, the plans of the National regulators and EMA, on-going discussions on pan-European HTA, and the trends for 2019.

Click the title above to open the Pharmaceutical January 2019 issue in an interactive PDF format.

Despite market access hurdles, Turkey’s pharmaceutical market holds tremendous growth potential-in both value and volume. But will the country be able to take that final step in creating a regulatory and economic environment that is conducive to further upward development?